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Of 908 patients who underwent operation for primary lung cancer between
January 1985 and June 1996, we considered 57 (6.3%) to have a second
primary lung cancer, which was synchronous in 28 cases (3.1%) and
metachronous in 29 cases (3.2%). Five-year survival for patients with
synchronous and metachronous disease from initial treatment of cancer
was 70.3% and 66.0%, respectively. Survival after the development of a
metachronous lesion was 32.9% at 5 years. Sixteen of the synchronous
second tumors (57%) were detected on preoperative radiography or bron-
choscopy and 11 (39%) at the time of operation. Survival of patients at stage
I or II from treatment of a synchronous lesion (p 5 0.002) and of a
metachronous second lesion (p 5 0.028) was significantly better compared
with those at stage III or IV. Therefore it is important to carefully examine
a synchronous lesion before and during the operation of a primary lung
cancer and to perform close follow-up surveillance for early detection of a
metachronous lesion. In treating multiple lung carcinomas consideration
should always be given to performing precise staging, aggressive operative
approach for early stage, and oncologically sound parenchymal sparing
procedures. (J Thorac Cardiovasc Surg 1998;115:836-40)
Although the idea of multiple primary lung carci-nomas, which was first described by Beyreuther1
in 1924, has been generally accepted, the prevalence
remains unclear and varies from 1% to 10% for
synchronous and metachronous cancers together.2-9
Despite a recently reported increase, most reports
of large series of patients with multiple primary lung
cancers did not use developed radiographic tech-
nique, such as computed tomography, in the past. If
they did it, they probably would have found a higher
prevalence of synchronous cancers in the preopera-
tive workup and of metachronous cancers during
follow-up. In addition, we followed the policy that
lung-saving procedures, such as bronchoplasty for a
primary lesion, must always be kept in mind. This
article summarizes our experience of evaluation and
operative treatment of patients in whom multiple
primary lung carcinomas were suspected over the
past 11 years.
Patients and methods
The medical records of all patients who underwent
operation for primary lung cancer at our center between
January 1985 and June 1996 were reviewed. All charts of
patients with a probable diagnosis of multiple primary
lung cancer were available for analysis. The following
criteria, based on and modified from those of Martini and
Melamed,4 have been used for designation of multiple
primary lung cancers: (1) The tumors were anatomically
separate (different lobes or lungs). (2) The tumors were
histologically different. If the tumors were histologically
the same, they must have no systemic metastases or
mediastinal spread. Where all the lesions were squamous
cell carcinomas, a classification was accepted if a separate
origin from an area of carcinoma in situ could be identi-
fied for each. In case of the metachronous tumors with the
same histologic findings, tumor-free interval was at least 2
years. Patients who did not meet these criteria were
excluded. All cancers were staged using the criteria of the
New International Staging System for Lung Cancer,10 and
staging was based on data obtained from imaging, bron-
choscopy, invasive diagnostic techniques, operative find-
ings, and pathologic findings. Careful intraoperative stag-
ing at the time of operative resection was done by
dissecting intrapulmonary, hilar, and mediastinal nodes.
Histologic typing was done according to the World Health
Organization classification.11 All cases of bronchioloal-
veolar carcinoma were excluded just because of the ques-
tion of multicentricity of those primary cancers. A syn-
From the Department of Thoracic Surgery, Hyogo Medical
Center for Adults, Akashi City, Hyogo, Japan.
Received for publication May 21, 1997; revisions requested July
22, 1997; revisions received Nov. 17, 1997; accepted for
publication Dec. 9, 1997.
Address for reprints: N. Tsubota, MD, Department of Thoracic
Surgery, Hyogo Medical Center for Adults, Kitaohji-cho
13-70, Akashi City 673, Hyogo, Japan.
Copyright © 1998 by Mosby, Inc.
0022-5223/98 $5.00 1 0 12/1/88048
8 3 6
chronous multiple primary lung cancer was identified if
there was radiographic evidence of a second primary
tumor before the first operation or if a second primary
tumor was discovered incidentally during operation or in
the resected specimen. The larger of two synchronous
tumors was considered the first primary cancer for the
purpose of analysis. All patients who underwent resection
for a primary lung cancer had a chest roentgenogram, a
history, and a physical examination at the follow-up visit,
which took place at least twice a year.
Cumulative survivals were calculated by the Kaplan-
Meier estimation, and differences in survival were deter-
mined by log-rank analysis.
Results
From January 1985 to June 1996, 908 patients
underwent operation for a primary lung cancer at
our center. Fifty-seven (6.3%) patients were found
to have a second primary lung cancer, three of these
also had a third cancer.12 Synchronous tumors com-
prised 28 of 908 (3.1%) and metachronous tumors
29 of 908 (3.2%). Overall follow-up ranged from 6 to
144 months, with a median of 51 months.
Synchronous carcinoma. The average age at ini-
tial treatment was 64.3 6 7.7 years (mean 6 stan-
dard error), with an age range of 47 to 76 years.
There were 24 male and 4 female patients. Squa-
mous cell carcinoma constituted 14 of 28 (50%) of
the first tumors and 12 of 28 (43%) of the second
tumors. Adenocarcinoma was seen in 11 of 28
(39%) of the first tumors and 15 of 28 (54%) of the
second tumors. The histologic findings of the syn-
chronous second tumor were the same as those of
the synchronous first tumor in 12 (43%) patients
and equally consisted of squamous cell carcinoma
and adenocarcinoma (Table I). Sixteen of the sec-
ond tumors (57%) were detected on preoperative
radiography or bronchoscopy, and 11 (39%) were
discovered during operation. In the other remaining
patient (4%), the second lesion was diagnosed inci-
dentally by histologic examination of the resected
specimen. The second tumor was on the same side
as the first tumor in 21 cases (75%). Stage I, II, IIIA,
or IIIB disease was noted in 11 (39%), 5 (18%), 5
(18%), or 3 tumors (11%), respectively (Table II).
The four remaining patients (14%) had double
tumors that were histologically different, and post-
operative pathologic examination showed additional
lesions that were diagnosed with pulmonary metas-
tasis. Staged resection was performed on 18% of
synchronous lesions (5 of 28) because they were
contralateral to the first tumor. Resection was per-
formed in all patients except for one with extended
disease. Lobectomy was by far the most common
procedure and was performed in 23 patients (82%),
including seven combined sleeve resections of the
bronchus. Two pneumonectomies including sleeve
technique for the bronchus and two segmentecto-
mies were carried out. Resection of the tumors was
possible in all patients, but two patients had pleural
dissemination. No postoperative deaths occurred
within 30 days after resection.
Overall 5-year survival was 70.3% for all patients
having a synchronous cancer (Fig. 1). The 5-year
survival of patients with stage I or II and stage III or
IV was 79.0% and 41.0%, respectively. Survival for
patients with stage I or II was significantly better
(p 5 0.002) compared with stage III or IV (Fig. 1).
Metachronous carcinoma. The average age at
the time of treatment for the first and second tumor
was 62.6 6 8.6 years (mean 6 standard error) with
an age range of 32 to 73 years, and 66.7 6 9.3 years
with an age range of 33 to 79 years, respectively. All
patients except one were men. The mean interval
between the initial treatment and the second was




Squamous cell carcinoma 6 (21) 14 (48)
Adenocarcinoma 12 (43) 2 (6)
Small cell carcinoma 0 2 (6)
Carcinoid 1 (4) 0
Adenosquamous carcinoma 1 (4) 0
Large cell carcinoma 0 1 (3)
Adenocarcinoma
Adenocarcinoma 6 (21) 5 (17)
Small cell carcinoma 1 (4) 3 (10)
Large cell carcinoma 1 (4) 1 (3)
Small cell carcinoma
Large cell carcinoma 0 1 (3)
Total 28 (100) 29 (100)
Numbers in parentheses are percentages.




Most advanced tumor First tumor Second tumor
I 11 (39) 15 (52) 17 (59)
II 5 (18) 6 (21) 1 (3)
IIIA 5 (18) 8 (28) 11 (38)
IIIB 3 (11) 0 0
IV 4 (14) 0 0
Total 28 (100) 29 (100) 29 (100)
Numbers in parentheses are percentages.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 4
Okada et al. 8 3 7
4.1 6 2.3 years. The longest interval was 10 years
and 8 months, and the shortest only 8 months. Every
case whose interval was less than 2 years had a
histologically different tumor. More than 5 years
after the first tumor, metachronous primary tumors
appeared in 13 patients (45%). Squamous cell car-
cinoma was the most common histologic type, mak-
ing up 17 (59%) of 29 patients as the first tumor and
16 (55%) patients as the second tumor. The next
most common histologic type was adenocarcinoma,
occurring in 8 (28%) and 8 (28%) of the first and
second tumors, respectively. The first and second
tumors shared the same histologic findings in 19
(63%) patients (Table I). The same histologic type
was more likely to occur if the first tumor was a
squamous cell carcinoma as opposed to an adeno-
carcinoma (14 of 17 patients, 82% and 5 of 8, 63%,
respectively). Stage I in first and second tumors
constituted 52% (15 of 29) and 59% (17 of 29),
respectively. No tumors were more advanced than
stage IIIA (Table II). Resection of the tumors was
possible in all patients. Obviously, more patients
underwent segmentectomy or wedge resection at
reoperation for the second disease compared with
initial operation. No postoperative deaths occurred
within 30 days after resection.
The 5-year actuarial survival after the initial and
the second resection was 66.0% and 32.9%, respec-
tively, for all patients with a metachronous cancer
(Fig. 2). Survival for patients with metachronous
disease determined from treatment of first tumors
was not significantly different from that of patients
with synchronous disease. Survival curves from
treatment of the first tumor indicated no significant
difference between patients with stage I or II and
stage III (Fig. 3). Patients with stage I or II and stage
III of the second tumor had survival rates of 49.8%
and 24.0% for 5 years, respectively. Survival from
treatment of the second tumor was significantly
better (p 5 0.028) for patients with stage I or II
compared with stage III (Fig. 4).
Discussion
Clinically, it is difficult to distinguish a second
primary carcinoma from a metastatic lesion arising
from a first tumor. Martini and Melamed4 in 1975
outlined the criteria for differentiation between the
two, which have been used by most subsequent
authors, including us. Pairolero and associates13
using criteria similar to ours, reported a 52% 2-year
survival for metachronous primary tumors com-
pared with 23% and 9% 2-year survival for local and
distant recurrent disease, respectively. These data
suggest that patients with multiple primary tumors
have a more favorable prognosis than patients with
locally recurrent or metastatic disease.14, 15 There-
fore an appropriate identification of multiple pri-
mary lung cancers is critical. In addition to the
application of stringent criteria for the diagnosis of
multiple primary lung cancers, incidence of this
disease may be affected by several factors, including
Fig. 1. Actuarial survival curves of patients in whom
synchronous multiple primary lung cancers developed.
Middle curve indicates survival for all patients with syn-
chronous disease. Top and bottom curves indicate the
survival of patients with stage I or II and stage III or IV,
respectively. Survival of patients with stage I or II was
significantly better (p 5 0.002) compared with stage III or
IV.
Fig. 2. Actuarial survival curves of patients in whom
metachronous multiple primary lung cancers developed.
Top and bottom curves indicate the survival from treat-
ment of the first and the second tumor, respectively.
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the sensitivity of diagnostic procedures, the pathol-
ogist’s skill, the efficacy of the treatment used, and
the length of the patient’s survival. These latter
factors, in particular the development of radiogra-
phy, would contribute to an increase in the inci-
dence of these multiple tumors, and therefore stan-
dardized criteria for the diagnosis of this disease
should be developed. In contrast to recent years,
most studies in the past did not use computed
tomography. If they did it preoperatively, they could
have found a higher prevalence of synchronous
tumors in the same way they might have found a
higher prevalence of metachronous cancers or might
have detected them earlier should they have used it
during follow-up. The developed radiographic tech-
nique in this series probably accounted for the
increased incidence of multiple primary tumors and
a high proportion of synchronous lesions.
The result that 57% of synchronous second le-
sions were discovered preoperatively and 39% intra-
operatively indicated the role of careful detection of
second lesions before and during the procedure for
a primary lung cancer. The inferior survival of
metachronous second lesions compared with first
lesions might be related to underestimating because
of technical difficulties during the second procedure
and to resorting to lesser resections because of
limited pulmonary reserve. The survival advantage
of metachronous lesions compared with synchro-
nous ones has been reported by others14, 16, 17 and
does not agree with our study. The possibility that
some patients with recurrent or metastatic disease
have also been included as subjects cannot be ruled
out for other published literature. We believe that
the difference between synchronous and metachro-
nous cancers is just an arbitrary one because it refers
to the moment of diagnosis and not to the moment
of development.
The question of whether a newly discovered lung
lesion after resection is actually a second primary
tumor or a recurrence remains a theoretical one.
We follow the policy of thoroughly restaging all such
lesions and operating with the intention to cure
whenever possible. Therefore, although patients
with unilateral lesions found in separate lobes
should be treated by pneumonectomy or bilobec-
tomy, lobectomy with additional wedge resection
may be done in patients with limited pulmonary
function. In patients with bilateral lesions a curative
resection should be done on the side that initially
appears to be more advanced. However, lung tissue
should not be sacrificed for expediency in these
patients. If a lung-saving procedure such as a sleeve
lobectomy for the first lesion is done and sufficient
pulmonary function is preserved, a second radical
operation is possible. Otherwise, there is no choice
except to perform conservative treatment, including
wedge resection, chemotherapy, radiation therapy
Fig. 3. Actuarial survival curves of patients in whom
metachronous multiple primary lung cancers developed
from treatment of the first tumor. Solid and dashed lines
indicate the survival in patients with stage I or II and stage
III of the first tumor, respectively. No significant differ-
ences in survival probability were found between stage I or
II and stage III.
Fig. 4. Actuarial survival curves of patients in whom
metachronous multiple primary lung cancers developed
from treatment of the second tumor. Solid and dashed
lines indicate the survival in patients with stage I or II and
stage III of the second tumor, respectively. Survival of
patients with stage I or II was significantly better (p 5
0.028) than that of patients with stage III disease.
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or all three. A curative yet limited extent of opera-
tion allowing for maximum preservation of pulmo-
nary function should be of prime consideration. This
strategy may allow subsequent treatment of the
second lesion by operation. Bronchoplasty, includ-
ing sleeve resection, has been used frequently at this
center not only for patients with limited pulmonary
reserve but also for those with sufficient reserve.18
Bronchoplasty on the first occasion would leave the
patient with more lung tissue to resect should a
second primary tumor develop later. This principle
of conservation is very important because the loss of
pulmonary function from more radical procedures
for the first lesion may be extensive or may prevent
a second operation. Re-resection can almost be
performed safely, as indicated by our series with no
operative deaths and others’ operative mortality
rates.2, 16
Survival for patients with early-stage multiple
primary tumors was significantly better than those
with advanced tumors, as has been reported by us
and others.2 These data highlight the need for
careful lifelong screening for a second lesion to
improve overall survival. We obtained very poor
results in the whole group of stage III or IV
synchronous tumors and of stage III metachronous
second tumors. The advance of staging and the
presence of a second primary tumor could influence
survival. Therefore, when a new primary lung tumor
has been found, precise staging is necessary and an
aggressive operative approach is indicated, espe-
cially for earlier second tumors.
We recommend that the resection be tissue-
sparing whenever it is reasonable to do so whether it
is the first or any subsequent operation. Therefore
we should avoid pneumonectomy and instead try to
use bronchoplasty as much as possible.
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